KOSDAQBiotech & Pharma183490

Enzychem Lifesciences

₩990 0.00%2026-11-18 close
Market Cap
₩83.8B
Turnover
₩0
Volume
0 shares
Shares out.
84.6M
PER
—
PBR
0.6×
EPS
-₩234
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses persist as clinical and licensing milestones pile up

Enzychem Lifesciences has posted annual losses from 2022 through 2025 and operating losses in each of the last five quarters. Its API business provides the sales base, while the EC-18 clinical program and licensing efforts carry the pipeline story.

  1. 1

    Sales fell 12.4% to KRW 67.8 billion in 2025, and operating losses continued at KRW 14.3 billion for a fourth straight year.

  2. 2

    Third-quarter 2026 sales rose 22.4% year on year to KRW 20.2 billion, yet the operating loss widened to KRW 4.51 billion.

  3. 3

    In a US Phase 2 trial that the company has disclosed, median severe oral mucositis duration in the top-dose EC-18 arm was zero days, against 13.5 days for placebo.

  4. 4

    The company had targeted a licensing (L/O) deal for its EC-X1 DAC pipeline within the first quarter of 2026, which makes a contract disclosure the next checkpoint.

  5. 5

    After a management-rights dispute and injunction proceedings, the company said in August 2026 that it would focus on resuming trading in its shares.

02

Business structure

Enzychem Lifesciences, founded in 1999, is a biopharmaceutical company whose revenue center is its active pharmaceutical ingredient (API) business. Alphasquare's breakdown shows bio-oil products (recovered oil) at 53.80% of sales and antitussive and anticoagulant ingredients at 46.20%.

A JobKorea snapshot as of March 2026 shows a different split: 68% bio-oil products, 22% antitussive and anticoagulant ingredients, 6% interior construction work and 5% cosmetics. The two splits differ by source and date, so segment weights should be read with that caveat.

Production runs at GMP plants in Jecheon, Chungcheongbuk-do, and the company says it holds Japan PMDA and EU GMP certifications that support overseas API supply. The company says it produces and sells more than 40 APIs in Korea and abroad.

The second pillar is drug discovery, centered on EC-18, a synthetic drug derived from deer antler; it is being developed for chemoradiotherapy-induced oral mucositis and acute radiation syndrome, and EC-18 holds FDA orphan drug designation for acute radiation syndrome.

The third pillar is ROCKPID, an immune-regulating health functional food targeting overseas consumer markets. On the platform side, the company is upgrading an antibody-drug conjugate (ADC) platform, and its first DAC pipeline candidate, EC-X1, targets EZH2.

The company is also expanding into regenerative biomaterials through PDRN and PN. Competition runs against synthetic API makers in ingredients and against domestic biotech firms with clinical-stage pipelines in drug discovery. The value of the pipeline ultimately depends on licensing results.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩16.5B-₩3.7B−22.6%
2025Q4₩14.1B-₩4.4B−31.1%
2026Q1₩14.9B-₩3.2B−21.8%
2026Q2₩23.5B-₩4.1B−17.3%
2026Q3₩20.2B-₩4.5B−22.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩26.6B-₩14.7B-₩25.1B−55.0%−12.4%22.7%
2023₩76B-₩14.4B-₩9.3B−18.9%−4.8%8.7%
2024₩77.4B-₩13.2B-₩22.1B−17.1%−13.8%12.5%
2025₩67.8B-₩14.3B-₩18.1B−21.2%−13.2%7.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual sales rose from KRW 26.6 billion in 2022 to KRW 76 billion in 2023, an increase of 185.5% year on year, and reached KRW 77.4 billion in 2024, up 1.8%. Sales then fell 12.4% to KRW 67.8 billion in 2025. Among 2022 through 2025, 2024 was the largest year and 2022 the smallest.

Operating losses were KRW 14.7 billion in 2022, KRW 14.4 billion in 2023, KRW 13.2 billion in 2024 and KRW 14.3 billion in 2025, a loss in each of the four years. The operating margin moved from -55.0% in 2022 to -18.9% in 2023, -17.1% in 2024 and -21.2% in 2025.

Sales grew sharply in 2023, yet the operating loss did not narrow by much, and in 2025 the margin turned lower again as sales declined. Net loss attributable to controlling shareholders was KRW 25.1 billion in 2022, KRW 9.33 billion in 2023, KRW 22.1 billion in 2024 and KRW 18.1 billion in 2025, a loss in each year.

In 2024 the attributable net loss of KRW 22.1 billion exceeded the operating loss of KRW 13.2 billion, which points to a sizable non-operating drag that year.

Operating cash flow was -KRW 14.3 billion in 2022, -KRW 10.3 billion in 2023, -KRW 574 million in 2024 and -KRW 11 billion in 2025, so outflows exceeded KRW 10 billion in every year except 2024.

At the end of 2025, total equity was KRW 138.8 billion, equity attributable to controlling shareholders was KRW 137.5 billion, total liabilities were KRW 9.83 billion, and the debt ratio was 7.1%.

By quarter, sales were KRW 16.5 billion in Q3 2025, KRW 14.1 billion in Q4 2025 (down 14.4% from the prior quarter), KRW 14.9 billion in Q1 2026, KRW 23.5 billion in Q2 2026 (up 58.1% from the prior quarter) and KRW 20.2 billion in Q3 2026 (down 14.4% quarter on quarter, up 22.4% year on year).

Operating losses over the same five quarters were KRW 3.72 billion, KRW 4.38 billion, KRW 3.24 billion, KRW 4.07 billion and KRW 4.51 billion, a loss in each quarter, and the Q3 2026 loss widened both from the prior quarter and from a year earlier.

The attributable net loss of KRW 9.9 billion in Q4 2025 was the largest among the five quarters, and the last four quarters totaled KRW 18.7 billion. Quarters in which sales recovered did not bring a narrower operating loss, which is the central earnings issue.

05

Industry analysis

The company's drug indications span chemoradiotherapy-induced oral mucositis, which accompanies cancer treatment, and acute radiation exposure response. In the company's disclosed Phase 2 results for chemoradiotherapy-induced oral mucositis, the EC-18 arm showed about a 35% improvement against the control group.

The acute radiation syndrome indication holds FDA orphan drug designation, but the company has not yet set out a concrete commercialization timeline. The API business relies on demand for established ingredients such as antitussives and anticoagulants, and unlike the drug pipeline it currently provides the sales base.

In biomaterials, the company is pushing a KRW 10 trillion PDRN and PN market, with full in-house process control, although that market size is the company's own figure.

Within the industry, Alphasquare's aggregation places the company at 92nd by market capitalization, 94th by sales and 118th by operating income among 139 pharmaceutical and health-functional-food companies on an annual basis.

Compared with large pharmaceutical companies such as Yuhan and Hanmi Pharm, the sales scale gap is wide. The CEO has said the company has yet to realize licensing-out results with a global big pharma, so the pace at which licensing results accumulate is the main point of differentiation. On the strength side, the GMP-certified API base supports sales independently of clinical progress.

06

Outlook

For 2026 the company set out a GLP-1 obesity drug convergence project and a plan to pursue a US strategic stockpile for EC-18 as its business targets. The company said that converting the EC-18 stockpile into an asset could support an initial market value of KRW 300 billion, a figure the company itself estimates.

The first DAC pipeline candidate, EC-X1, was targeted for a licensing (L/O) contract within the first quarter of 2026, and since that target date has passed, the signing and terms of such a contract are the next checkpoint.

On radiation response, the company set endpoints for survival and gastrointestinal injury in a rodent acute radiation syndrome study and said it would move to the next stage under the FDA animal rule review pathway.

In mid-2026 it announced follow-up work on a radiation intestinal injury treatment, and it later said it would co-develop a radiation dermatitis treatment with the Korea Institute of Radiological and Medical Sciences.

On ROCKPID, the company is developing a metabolic-health functional food and a film-type immune health product.

The CEO named successful global licensing-out of the existing pipeline, results in acute radiation syndrome treatment, and visible results from the DAC and PROTAC pipelines as key tasks, and stated a goal of returning to profitability.

The turn to profit is not yet reflected in disclosed results, so the operating loss trend in the 2026 annual report is the first indicator to check.

07

Valuation

PER
—
PBR
0.6×
ROE
-12.9%
EPS
-₩234
BPS
₩1,708
Dividend per share
₩0

The company has posted net losses over the last four quarters, so a price-to-earnings ratio cannot be calculated. On a book basis, the price-to-book ratio is below 1x, and Alphasquare's aggregation puts it below the sector average.

Market capitalization sits below the KRW 137.5 billion of equity attributable to controlling shareholders, so the shares trade at a discount to net asset value. The dividend yield is far below the sector average because the company has no dividend record.

Since the company has not returned to profit, valuation reads rest more on assets and pipeline value than on earnings. That discount may also reflect the ongoing losses and the management-rights dispute and trading suspension. The key dividing line for valuation is whether pipeline and licensing results translate into actual cash flow.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

EC-18 clinical data

In a US Phase 2 study of 105 head and neck cancer patients that the company has disclosed, the median duration of severe oral mucositis in the top-dose EC-18 arm was zero days, against 13.5 days for placebo. The company also cites about a 35% improvement over the control group in its oral mucositis Phase 2 work.

These results come from company disclosures, so independent verification and regulatory approval remain separate steps.

Quarterly sales recovery

Second-quarter 2026 sales reached KRW 23.5 billion, up 58.1% from the prior quarter, and third-quarter sales reached KRW 20.2 billion, up 22.4% year on year. That contrasts with the 12.4% annual sales decline in 2025.

Quarterly sales rebounded after the first half of 2026, and whether that recovery narrows losses remains the open question.

Licensing and partnership options

The EC-X1 DAC pipeline targets EZH2, which is overexpressed in solid tumors such as prostate and pancreatic cancer, and the company had aimed to complete a licensing deal in the first quarter of 2026.

External collaborations continue, including a radiation dermatitis co-development and a role as a joint research institution in a national dengue fever program. The bull case is that a licensing deal could bring cash inflows and validate the pipeline at the same time.

09

Bear factors

Persistent losses and cash outflows

Net loss attributable to controlling shareholders has been negative for four straight years from 2022 through 2025, and the last four quarters total KRW 18.7 billion. Operating cash flow was -KRW 11 billion in 2025, so cash outflows continued. The Q3 2026 operating loss of KRW 4.51 billion widened both from the prior quarter and from a year earlier.

Sales volatility and product concentration

Sales fell 12.4% to KRW 67.8 billion in 2025. Alphasquare's breakdown shows bio-oil products accounting for more than half of sales, which leaves revenue exposed to demand shifts in a single product line. Quarterly sales also swung widely, from KRW 14.1 billion in Q4 2025 to KRW 23.5 billion in Q2 2026.

Governance clean-up and delayed licensing

The company went through a management-rights dispute and injunction proceedings and has said it is preparing to resume trading. The CEO expressed regret that licensing-out results with a global big pharma have not yet been achieved. Without licensing results on record, the pipeline's value remains at the expectation stage.

10

Risk factors

Clinical and regulatory

EC-18 clinical results rest mainly on company disclosures, and both the oral mucositis and radiation indications still have regulatory steps ahead. The radiation indication must go through the FDA animal rule pathway, and it is uncertain whether rodent study results will carry into clinical design. Delays at any stage would push back the valuation of the pipeline.

Trading resumption and governance

The management-rights dispute and injunction proceedings could shape the timing of trading resumption and the shareholder base. The company reported 52% approval at the shareholders meeting, but whether governance has stabilized needs to be confirmed through later disclosures. Liquidity and price formation could change before and after trading resumes.

Financial structure and concentration

Operating cash outflows exceeded KRW 10 billion in three of the four years, excluding 2024. In a structure with heavy API sales concentration, a sales decline could widen losses. Total equity of KRW 138.8 billion at the end of 2025 and a debt ratio of 7.1% act as a cushion.

11

What to watch next

  1. After December 2026 (resumption date not yet set)

    Disclosure of the trading resumption decision and schedule. This is where governance stability after the dispute and the change in trading conditions can be assessed.

  2. After December 2026 (contract timing not yet set)

    Disclosure of a licensing contract for the EC-X1 DAC pipeline. Since completion within the first quarter of 2026 was the stated target, whether a deal is signed and on what terms is the starting point for judging pipeline value.

  3. After December 2026 (timing not yet set)

    Disclosures on entry into the FDA animal rule process for EC-18's radiation follow-up work and on a global commercialization partnership for the oral mucositis treatment. These show progress on the next stages that support the pipeline's value.

  4. End of March 2027 (annual report filing deadline)

    Annual sales and operating loss in the 2026 annual report. This shows how the quarterly loss streak that began in Q3 2025 is reflected on a full-year basis, along with the size of the attributable net loss.

12

Overall view

Enzychem Lifesciences posted annual operating and attributable net losses from 2022 through 2025, and operating losses in each of the five quarters from Q3 2025 through Q3 2026.

Sales fell from KRW 77.4 billion in 2024 to KRW 67.8 billion in 2025, but Q2 2026 sales rose to KRW 23.5 billion and Q3 2026 sales were also up year on year.

The API business maintains the sales base, while the EC-18 clinical results, the DAC pipeline licensing and the radiation response indications form the core of the pipeline value. On the other side, the Q3 2026 loss widened, and the last four quarters total KRW 18.7 billion in attributable net losses.

The company is preparing to resume trading after a management-rights dispute, so governance normalization is another factor to watch. A price-to-book ratio below 1x reflects the asset base, but without a return to profit, whether pipeline results convert into earnings is the central variable.

The next checkpoints are the operating loss in the 2026 annual report, any licensing contract disclosure, and the trading resumption schedule.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. plaglab.co.kr
  2. enzychem.co.kr
  3. jobplanet.co.kr
  4. dart.fss.or.kr
  5. catch.co.kr
  6. thevc.kr
  7. ibric.org
  8. incruit.com
  9. alphasquare.co.kr
  10. etoday.co.kr
  11. pharmnews.com
  12. joongangenews.com
  13. enzychem.co.kr
  14. enzychem.co.kr
  15. enzychem.com
  16. doctorstimes.com
  17. jobkorea.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis